Literature DB >> 20714935

Emergence of secondary resistance to imatinib in recurrent gastric GIST.

Naga Venkatesh Gupta Jayanthi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20714935     DOI： 10.1007/s11605-010-1302-z

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN： 1091-255X            Impact factor:   3.452


× No keyword cloud information.
  8 in total

1.  Sunitinib for imatinib-resistant GIST.

Authors:  Heikki Joensuu
Journal:  Lancet       Date:  2006-10-14       Impact factor: 79.321

2.  Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

Authors:  Markku Miettinen; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

3.  Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

Authors:  Markku Miettinen; Hala Makhlouf; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2006-04       Impact factor: 6.394

Review 4.  Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Arch Pathol Lab Med       Date:  2006-10       Impact factor: 5.534

5.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Robert G Maki; Christopher L Corless; Cristina R Antonescu; Amy Harlow; Diana Griffith; Ajia Town; Arin McKinley; Wen-Bin Ou; Jonathan A Fletcher; Christopher D M Fletcher; Xin Huang; Darrel P Cohen; Charles M Baum; George D Demetri
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

6.  Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

Authors:  S George; J Y Blay; P G Casali; A Le Cesne; P Stephenson; S E Deprimo; C S Harmon; C N J Law; J A Morgan; I Ray-Coquard; V Tassell; D P Cohen; G D Demetri
Journal:  Eur J Cancer       Date:  2009-03-11       Impact factor: 9.162

Review 7.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

8.  Emergence of imatinib resistance associated with downregulation of c-kit expression in recurrent gastrointestinal stromal tumor (GIST): optimal timing of resection.

Authors:  Vikas Dudeja; Leonard H Armstrong; Pankaj Gupta; Howard Ansel; Sabeen Askari; Waddah B Al-Refaie
Journal:  J Gastrointest Surg       Date:  2009-12-22       Impact factor: 3.452
  8 in total
  1 in total

1.  Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers.

Authors:  Safinur Atay; Daniel W Wilkey; Mohammed Milhem; Michael Merchant; Andrew K Godwin
Journal:  Mol Cell Proteomics       Date:  2017-12-14       Impact factor: 5.911
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.